INTERVACC AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.175 SEK | +3.34% |
|
+0.85% | -34.04% |
| Mar. 04 | Intervacc AB Announces Changes in the Nomination Committee | CI |
| Feb. 28 | Intervacc's Acting CEO Assumes Role Permanently | MT |
| Sales 2024 * | 19.2M 1.76M | Sales 2025 * | 53.1M 4.87M | Capitalization | 306M 28.06M |
|---|---|---|---|---|---|
| Net income 2024 * | -77M -7.06M | Net income 2025 * | -66M -6.05M | EV / Sales 2024 * | 9.89 x |
| Net cash position 2024 * | 116M 10.64M | Net cash position 2025 * | 55M 5.04M | EV / Sales 2025 * | 4.73 x |
| P/E ratio 2024 * |
-3.96
x | P/E ratio 2025 * |
-4.64
x | Employees | 15 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 78.16% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +2.60% | ||
| 1 week | +0.12% | ||
| Current month | +12.03% | ||
| 1 month | +13.25% | ||
| 3 months | -25.32% | ||
| 6 months | -29.15% | ||
| Current year | -34.52% |
1 week
3.86
4.38
1 month
3.604.90
Current year
3.206.76
1 year
3.2010.46
3 years
3.2095.50
5 years
3.2095.50
10 years
2.8895.50
| Managers | Title | Age | Since |
|---|---|---|---|
Jonas Sohlman
CEO | Chief Executive Officer | - | 23-08-20 |
Jan Persson
DFI | Director of Finance/CFO | - | 20-02-05 |
Andrew Waller
CTO | Chief Tech/Sci/R&D Officer | - | 20-06-10 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Boel Sundvall
BRD | Director/Board Member | 65 | 22-12-31 |
| Chairman | 56 | - | |
Edwin Torr
BRD | Director/Board Member | 63 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 4.175 | +3.34% | 107 518 |
| 24-04-25 | 4.04 | -0.49% | 57,552 |
| 24-04-24 | 4.06 | +0.50% | 60,495 |
| 24-04-23 | 4.04 | +0.87% | 51,980 |
| 24-04-22 | 4.005 | -3.26% | 93,281 |
Delayed Quote Nasdaq Stockholm, April 26, 2024 at 09:07 am EDT
More quotes
Intervacc AB is a Sweden-based biotechnology company. It develops vaccines based on recombinant proteins for animal health care. The Companyâs candidate vaccine against strangles Strangvac consists of soluble recombinant proteins and devoids any living infectious agent. The Company operates through two subsidiaries: Nord Vacc Lakemedel AB and Mybac-Vettech AB. Nord Vacc Lakemedel AB markets and distributes veterinary vaccines, pharmaceuticals and vitamins on European market. It offers assortment of fur animal vaccines, the Febrivac range, as well as swine vaccines for Swedish and Danish markets. Mybac-Vettech AB is a technology platform that focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses.
Calendar
2024-05-16
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
D
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -34.52% | 28.06M | |
| -2.26% | 103B | |
| +1.41% | 95.71B | |
| +0.73% | 22.02B | |
| -17.84% | 20.9B | |
| -9.26% | 17.85B | |
| -42.83% | 16.21B | |
| -17.63% | 15.52B | |
| +4.55% | 13.86B | |
| +32.11% | 12.04B |
- Stock Market
- Equities
- IVACC Stock
